DNA aptamer-based sandwich microfluidic assays for dual quantification and multi-glycan profiling of cancer biomarkers

Pawan Jolly, P. Damborsky, N. Madaboosi, R.R.G. Soares, V. Chu, J.P. Conde, J. Katrlik, Pedro Estrela

Research output: Contribution to journalArticle

25 Citations (Scopus)
101 Downloads (Pure)

Abstract

Two novel sandwich-based immunoassays for prostate cancer (PCa) diagnosis are reported, in which the primary antibody for capture is replaced by a DNA aptamer. The assays, which can be performed in parallel, were developed in a microfluidic device and tested for the detection of free Prostate Specific Antigen (fPSA). A secondary antibody (Aptamer–Antibody Assay) or a lectin (Aptamer–Lectin Assay) is used to quantify, by chemiluminescence, both the amount of fPSA and its glycosylation levels. The use of aptamers enables a more reliable, selective and controlled sensing of the analyte. The dual approach provides sensitive detection of fPSA along with selective fPSA glycoprofiling, which is of significant importance in the diagnosis and prognosis of PCa, as tumor progression is associated with changes in fPSA glycosylation. With these approaches, we can potentially detect 0.5 ng/mL of fPSA and 3 ng/mL of glycosylated fPSA using Sambucus nigra (SNA) lectin, both within the relevant clinical range. The approach can be applied to a wide range of biomarkers, thus providing a good alternative to standard antibody-based immunoassays with significant impact in medical diagnosis and prognosis.
Original languageEnglish
Pages (from-to)313-319
Number of pages7
JournalBiosensors and Bioelectronics
Volume79
Early online date19 Dec 2015
DOIs
Publication statusPublished - 16 May 2016

Fingerprint

Nucleotide Aptamers
Microfluidics
Prostate-Specific Antigen
Antigens
Tumor Biomarkers
Polysaccharides
Assays
DNA
Antibodies
Glycosylation
Lab-On-A-Chip Devices
Immunoassay
Lectins
Prostatic Neoplasms
Chemiluminescence
Biomarkers
Luminescence
Tumors

Keywords

  • microfluidics
  • DNA aptamers
  • glycoprofiling
  • sandwich assay
  • ELISA
  • Prostate cancer

Cite this

DNA aptamer-based sandwich microfluidic assays for dual quantification and multi-glycan profiling of cancer biomarkers. / Jolly, Pawan; Damborsky, P.; Madaboosi, N.; Soares, R.R.G.; Chu, V.; Conde, J.P.; Katrlik, J.; Estrela, Pedro.

In: Biosensors and Bioelectronics, Vol. 79, 16.05.2016, p. 313-319.

Research output: Contribution to journalArticle

Jolly, Pawan ; Damborsky, P. ; Madaboosi, N. ; Soares, R.R.G. ; Chu, V. ; Conde, J.P. ; Katrlik, J. ; Estrela, Pedro. / DNA aptamer-based sandwich microfluidic assays for dual quantification and multi-glycan profiling of cancer biomarkers. In: Biosensors and Bioelectronics. 2016 ; Vol. 79. pp. 313-319.
@article{736e6a40198b473291c4c888cace618a,
title = "DNA aptamer-based sandwich microfluidic assays for dual quantification and multi-glycan profiling of cancer biomarkers",
abstract = "Two novel sandwich-based immunoassays for prostate cancer (PCa) diagnosis are reported, in which the primary antibody for capture is replaced by a DNA aptamer. The assays, which can be performed in parallel, were developed in a microfluidic device and tested for the detection of free Prostate Specific Antigen (fPSA). A secondary antibody (Aptamer–Antibody Assay) or a lectin (Aptamer–Lectin Assay) is used to quantify, by chemiluminescence, both the amount of fPSA and its glycosylation levels. The use of aptamers enables a more reliable, selective and controlled sensing of the analyte. The dual approach provides sensitive detection of fPSA along with selective fPSA glycoprofiling, which is of significant importance in the diagnosis and prognosis of PCa, as tumor progression is associated with changes in fPSA glycosylation. With these approaches, we can potentially detect 0.5 ng/mL of fPSA and 3 ng/mL of glycosylated fPSA using Sambucus nigra (SNA) lectin, both within the relevant clinical range. The approach can be applied to a wide range of biomarkers, thus providing a good alternative to standard antibody-based immunoassays with significant impact in medical diagnosis and prognosis.",
keywords = "microfluidics, DNA aptamers, glycoprofiling, sandwich assay, ELISA, Prostate cancer",
author = "Pawan Jolly and P. Damborsky and N. Madaboosi and R.R.G. Soares and V. Chu and J.P. Conde and J. Katrlik and Pedro Estrela",
year = "2016",
month = "5",
day = "16",
doi = "10.1016/j.bios.2015.12.058",
language = "English",
volume = "79",
pages = "313--319",
journal = "Biosensors and Bioelectronics",
issn = "0956-5663",
publisher = "Elsevier",

}

TY - JOUR

T1 - DNA aptamer-based sandwich microfluidic assays for dual quantification and multi-glycan profiling of cancer biomarkers

AU - Jolly, Pawan

AU - Damborsky, P.

AU - Madaboosi, N.

AU - Soares, R.R.G.

AU - Chu, V.

AU - Conde, J.P.

AU - Katrlik, J.

AU - Estrela, Pedro

PY - 2016/5/16

Y1 - 2016/5/16

N2 - Two novel sandwich-based immunoassays for prostate cancer (PCa) diagnosis are reported, in which the primary antibody for capture is replaced by a DNA aptamer. The assays, which can be performed in parallel, were developed in a microfluidic device and tested for the detection of free Prostate Specific Antigen (fPSA). A secondary antibody (Aptamer–Antibody Assay) or a lectin (Aptamer–Lectin Assay) is used to quantify, by chemiluminescence, both the amount of fPSA and its glycosylation levels. The use of aptamers enables a more reliable, selective and controlled sensing of the analyte. The dual approach provides sensitive detection of fPSA along with selective fPSA glycoprofiling, which is of significant importance in the diagnosis and prognosis of PCa, as tumor progression is associated with changes in fPSA glycosylation. With these approaches, we can potentially detect 0.5 ng/mL of fPSA and 3 ng/mL of glycosylated fPSA using Sambucus nigra (SNA) lectin, both within the relevant clinical range. The approach can be applied to a wide range of biomarkers, thus providing a good alternative to standard antibody-based immunoassays with significant impact in medical diagnosis and prognosis.

AB - Two novel sandwich-based immunoassays for prostate cancer (PCa) diagnosis are reported, in which the primary antibody for capture is replaced by a DNA aptamer. The assays, which can be performed in parallel, were developed in a microfluidic device and tested for the detection of free Prostate Specific Antigen (fPSA). A secondary antibody (Aptamer–Antibody Assay) or a lectin (Aptamer–Lectin Assay) is used to quantify, by chemiluminescence, both the amount of fPSA and its glycosylation levels. The use of aptamers enables a more reliable, selective and controlled sensing of the analyte. The dual approach provides sensitive detection of fPSA along with selective fPSA glycoprofiling, which is of significant importance in the diagnosis and prognosis of PCa, as tumor progression is associated with changes in fPSA glycosylation. With these approaches, we can potentially detect 0.5 ng/mL of fPSA and 3 ng/mL of glycosylated fPSA using Sambucus nigra (SNA) lectin, both within the relevant clinical range. The approach can be applied to a wide range of biomarkers, thus providing a good alternative to standard antibody-based immunoassays with significant impact in medical diagnosis and prognosis.

KW - microfluidics

KW - DNA aptamers

KW - glycoprofiling

KW - sandwich assay

KW - ELISA

KW - Prostate cancer

UR - http://dx.doi.org/10.1016/j.bios.2015.12.058

U2 - 10.1016/j.bios.2015.12.058

DO - 10.1016/j.bios.2015.12.058

M3 - Article

VL - 79

SP - 313

EP - 319

JO - Biosensors and Bioelectronics

JF - Biosensors and Bioelectronics

SN - 0956-5663

ER -